Supraclavicular lymphadenopathy after COVID‐19 vaccination

Larkin, Kelsey; Sharma, Archana; Drachtman, Richard A.; Salaru, Gratian

doi:10.1002/pbc.29516

Cited by 4 publications

(21 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After excluding 74 articles for the reasons stated in Figure 1 , and with the addition of 5 articles identified from the reference lists of articles, 39 articles were included in this review and 21 COVID-19 studies were included in the pooled analysis. A total of 25 studies [ 18 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ] were relevant to the COVID-19 vaccine and 14 studies [ 7 , 8 , 9 , 10 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 ] were related to non-COVID-19 vaccines.…”

Section: Resultsmentioning

confidence: 99%

“…The 25 studies were published by authors from countries including Germany [ 18 ] ( n = 1), Israel [ 22 , 37 ] ( n = 2), Japan [ 26 ] ( n = 1), Portugal [ 20 ] ( n = 1), Qatar [ 31 ] ( n = 1), Singapore [ 32 , 33 ] ( n = 2), South Korea [ 27 , 30 , 39 ] ( n = 3), Spain [ 23 , 24 , 41 ] ( n = 3), Switzerland [ 21 ] ( n = 1), the United Kingdom [ 36 ] (UK) ( n = 1), and the United States of America [ 25 , 28 , 29 , 34 , 35 , 38 , 40 , 43 ] (USA) ( n = 8). Most studies are case reports ( n = 12, 48.0%), followed by case series ( n = 9, 36.0%), retrospective studies ( n = 3, 12.0%), and not reported in one study (4.0%).…”

Section: Resultsmentioning

confidence: 99%

“…Findings from the pooled analysis are summarized in Table 1 . Pooled analysis of 21 studies [ 18 , 20 , 21 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ] included 37 patients with a mean age of 47.8 ± 19.1 years old, of which 23 were female (23/37, 62.2%). The largest proportion of patients (9/37, 24.3%) had no prior medical history, followed by 21.6% (8/37) with a history of melanoma, and 18.9% (7/37) with a history of breast cancer.…”

Section: Resultsmentioning

confidence: 99%

“…Additional clinical symptoms aside from lymphadenopathy were reported in these cases. Overall, six patients (6/37, 16.2%) experienced fever [ 25 , 30 , 33 , 34 ], while four patients (4/37, 10.8%) also reported pain [ 26 , 27 , 28 , 29 ]. The other described symptoms included fatigue or malaise (2/37, 5.4%), myalgia (2/37, 5.4%), dysphagia (1/37, 2.7%), chills (1/37, 2.7%), and other symptoms such as vomiting (2/37, 5.4%).…”

Section: Resultsmentioning

confidence: 99%

“…A total of 15 studies reported pathological findings of C19-VAL. There was a total of eight case reports [ 20 , 25 , 26 , 27 , 30 , 31 , 32 , 34 ], five case series [ 21 , 24 , 28 , 29 , 33 ], one retrospective study [ 22 ], and one study type was not reported. Our findings are summarized in Table 2 .…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Chua

Takano

2022

JCM

View full text Add to dashboard Cite

COVID-19 vaccine-associated lymphadenopathy (C19-VAL) is increasingly encountered with the widespread use of the vaccine in controlling the outbreak. We aim to characterize the pathological findings of COVID-19 and non-COVID-19 vaccine-associated lymphadenopathy (NC19-VAL). A search for studies that reported pathological findings in vaccine-associated lymphadenopathy on PubMed and Google Scholar was performed on December 11, 2021. C19-VAL studies were pooled for analysis. These studies were split into clinical lymphadenopathy (CL) and subclinical lymphadenopathy detected on imaging (SLDI) for subgroup analysis. A total of 25 studies were related to COVID-19 vaccines, and 21 studies were included in the pooled analysis. The pooled analysis included 37 patients with a mean age of 47.8 ± 19.1 years old, and 62.2% were females. The mean duration from last vaccination to development of CL/SLDI was 14.5 ± 11.0 days. Most were diagnosed as reactive or negative for malignancy (28/37, 75.5%), followed by Kikuchi–Fujimoto disease (KFD) (3/37, 8.1%), florid lymphoid hyperplasia (2/37, 5.4%), and granulomatous inflammation (2/37, 5.4%). Metastases were reported in two patients with a history of malignancy (2/37, 5.4%). Cases with florid lymphoid hyperplasia and KFD were younger than those with reactive changes. A total of 14 studies were related to non-COVID-19 vaccines. Caseating granulomatous inflammation was reported in BCG vaccine-associated lymphadenopathy, while other vaccines were associated with reactive lymphoid hyperplasia, florid post-vaccinal reactions, and KFD. Although most C19-VAL cases were reported as reactive or negative for malignancy, other diagnoses included florid lymphoid hyperplasia, KFD, and granulomatous inflammation. Metastases were reported in lymphadenopathy of patients with a history of malignancy, who had been incidentally vaccinated. In conclusion, C19-VAL can yield different histopathological diagnoses when sampled, most of which require clinical and radiological correlation for optimal patient management.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Chua

Takano

2022

JCM

View full text Add to dashboard Cite

show abstract

Coronavirus-vaccine

2022

Reactions Weekly

View full text Add to dashboard Cite

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy

Ripabelli

Sammarco

D'Amico

et al. 2022

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

This survey investigated on adverse events after vaccination with mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine in children aged 5–11 years in central Italy through active surveillance reporting. During December 2021–January 2022, parents of children who undergone vaccination were interviewed using a structured questionnaire. 197 out of 208 contacted parents participated (94.7% response rate), of whom 166 (84.3%) had one child. Of the 229 children, the mean age was 8.9 years, 50.7% were female. 193 (84.3%) had at least one adverse event after the first dose (mean age 9.1 years; 54.4% female), and 146 (73.4%) of 199 after the second (mean age 8.9 years; 54.8% female), which was not administered to 30 children due to previous COVID-19 history. Local symptoms after the first and second dose occurred in 183 (94.8%) and 141 (96.6%) recipients (p = .435), respectively, while systemic reactions in 62 (32.1%) and 34 (23.3%) ( p = .074). Mild events were reported by 81.7% and 69.8% children after the first and second dose, followed by moderate (3.9% and 10.6%) and severe (1.3% and 0.5%). After each dose, injection site reactions (79.5% and 68.8%) were the most frequent, followed by headache (13.1%) and lymphadenopathy (8.5%) after the first and second dose, respectively. The adverse events were reported to pediatricians only for 5.7% and 3.9% of children and treated for 17.6% and 15.8%. This is the first report about safety profile through active surveillance of mRNA BNT162b2 among children in Italy, revealing temporary and mild-to-moderate symptoms with no serious events after each vaccine dose.

show abstract

Supraclavicular lymphadenopathy after COVID‐19 vaccination

Cited by 4 publications

References 6 publications

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Pathological Findings in COVID-19 and Non-COVID-19 Vaccine-Associated Lymphadenopathy: A Systematic Review

Coronavirus-vaccine

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5–11 years: Results from an active pharmacovigilance study in central Italy

Contact Info

Product

Resources

About